文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

2023年南半球流感疫苗对严重流感相关疾病的有效性:基于八个国家采用检测阴性设计的合并估计

Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design.
PubMed 文献 · Lancet Glob Health · 2025-01-01

研究采用检测阴性设计,在阿根廷、澳大利亚、巴西、智利、新西兰、巴拉圭、泰国和乌拉圭八个使用2023年南半球流感疫苗配方的国家评估季末疫苗有效性。2023年3月5日至11月27日,共纳入12609例因严重急性呼吸道感染住院且符合标准并有完整数据的患者(4388例检测阳性病例和8221例检测阴性对照)。合并疫苗对任何流感病毒住院的有效性为51.9%(95%CI 37.2-66.7),各国间异质性I²=74%;对任何流感病毒入住ICU的有效性在智利为67.7%(44.5-81.2),在澳大利亚为69.7%(45.3-83.3)。

要点

  • 2023年南半球流感疫苗对任何流感病毒住院的合并有效性为51.9%(95%CI 37.2-66.7),各国间异质性I²=74%。
  • 对任何流感病毒入住ICU的有效性:智利67.7%(44.5-81.2),澳大利亚69.7%(45.3-83.3)。
  • 住院有效性估计在1-4岁幼儿中最高(70.9% [47.5-94.4]),在≥65岁老年人中最低(47.7% [24.9-70.5])。

核心结论

  • 在八个国家中,2023年南半球流感疫苗有效减少了流感疾病导致的住院。
  • 使用共同方案有助于数据合并,从而提供跨环境的疫苗有效性综合评估。

研究设计与样本

  • 采用检测阴性设计,评估八个国家(阿根廷、澳大利亚、巴西、智利、新西兰、巴拉圭、泰国和乌拉圭)使用2023年南半球流感疫苗配方的季末流感疫苗有效性。
  • 所有因严重急性呼吸道感染到参与医院就诊的患者均接受RT-PCR流感检测。
  • 计算国家特异性、网络特异性和合并的疫苗对住院的有效性;对于数据充足的国家,通过比较检测阳性病例与检测阴性对照的接种 odds 计算对ICU入住的有效性。
  • 评估优先接种人群(1-4岁幼儿、5-64岁有基础疾病者、≥65岁老年人)的疫苗有效性。
  • 2023年3月5日至11月27日,八个国家共31368例因严重急性呼吸道感染住院;其中12609例符合纳入标准且有完整数据的住院患者(6452例[51.2%]女性,6157例[48.8%]男性)纳入分析,包括4388例检测阳性病例和8221例检测阴性对照。

主要发现

  • 对任何流感病毒住院的合并疫苗有效性为51.9%(95%CI 37.2-66.7),各国间存在显著异质性(I²=74%)。
  • 对任何流感病毒入住ICU的疫苗有效性在智利为67.7%(44.5-81.2),在澳大利亚为69.7%(45.3-83.3)。
  • 对住院的疫苗有效性估计在1-4岁幼儿中最高(70.9% [47.5-94.4]),在≥65岁老年人中最低(47.7% [24.9-70.5])。

关键数值与推荐

  • 对任何流感病毒住院的合并疫苗有效性为51.9%(95%CI 37.2-66.7),异质性I²=74%。
  • 对任何流感病毒入住ICU的疫苗有效性:智利67.7%(44.5-81.2),澳大利亚69.7%(45.3-83.3)。
  • 对住院的疫苗有效性:1-4岁幼儿70.9%(47.5-94.4),≥65岁老年人47.7%(24.9-70.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Annual estimates of seasonal influenza vaccine effectiveness can guide global risk communication and vaccination strategies to mitigate influenza-associated illness. We aimed to evaluate vaccine effectiveness in countries using the 2023 southern hemisphere influenza vaccine formulation. METHODS: We evaluated end-of-season influenza vaccine effectiveness across eight countries (Argentina, Australia, Brazil, Chile, New Zealand, Paraguay, Thailand, and Uruguay) that used the 2023 southern hemisphere vaccine formulation, with use of a test-negative design. All patients who attended participating hospitals with severe acute respiratory illness were tested by RT-PCR for influenza. We calculated country-specific, network-specific, and pooled vaccine effectiveness against hospitalisation. For countries with sufficient data, we also calculated vaccine effectiveness against intensive care unit (ICU) admission by comparing the odds of vaccination among test-positive cases to that among test-negative controls. We evaluated vaccine effectiveness for groups prioritised for vaccination (young children aged 1-4 years, people aged 5-64 years with underlying health conditions, and older adults aged ≥65 years). FINDINGS: From March 5 to Nov 27, 2023, 31 368 individuals were admitted to hospital with severe acute respiratory infection in the eight included countries. Of these, 12 609 individuals admitted to hospital (6452 [51·2%] female and 6157 [48·8%] male) who met inclusion criteria and had complete data were included in the analysis, including 4388 test-positive cases and 8221 test-negative controls. Pooled vaccine effectiveness against hospitalisation with any influenza virus was 51·9% (95% CI 37·2-66·7), with substantial heterogeneity across countries (I2 74%). Vaccine effectiveness against ICU admission from any influenza virus was 67·7% (44·5-81·2) in Chile and 69·7% (45·3-83·3) in Australia. Vaccine effectiveness estimates against hospitalisation were highest for young children (70·9% [47·5-94·4]) and lowest for older adults (47·7% [24·9-70·5]). INTERPRETATION: Across eight countries, 2023 southern hemisphere vaccines were effective in reducing hospitalisations from influenza illness. Use of common protocols can facilitate data pooling to provide a comprehensive evaluation of vaccine effectiveness across settings. FUNDING: US Centers for Disease Control and Prevention cooperative agreements to the Pan American Health Organization and the Thailand Ministry of Public Health; the Australian Government Department of Health and Aged Care; and the New Zealand Ministry of Health.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Gharpure R, Regan AK, Nogareda F, et al. Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design. Lancet Glob Health. 2025. PMID: 39890222. doi:10.1016/S2214-109X(24)00473-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。